Evidence map›Paper›PMID 24278217›Full record

ArticlePloS one2013

Resequencing three candidate genes for major depressive disorder in a Dutch cohort.

Eva C Verbeek, Marianna R Bevova, Zoltán Bochdanovits, Patrizia Rizzu, Ingrid M C Bakker, Tiny Uithuisje, Eco J De Geus, Johannes H Smit, Brenda W Penninx, Dorret I Boomsma and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Genetic Studies on the Tripartite Glutamate Synapse in the Pathophysiology and Therapeutics of Mood Disorders.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017
    Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Eva C VerbeekDepartment of Clinical Genetics, VU University Medical Center, Amsterdam, The Netherlands.
Marianna R Bevova
Zoltán Bochdanovits
Patrizia Rizzu
Ingrid M C Bakker
Tiny Uithuisje
Eco J De Geus
Johannes H Smit
Brenda W Penninx
Dorret I Boomsma
Witte J G Hoogendijk
Peter Heutink
Amsterdam UMC Location VUmc · NL

Funding

Major Depression: Stage 1 Genomewide Association in Population-Based SamplesR01MH081802 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SULLIVAN, PATRICK F · 2007 to 2007
$138k
NIMH NIH HHS R01 MH081802
6 · The paper itself

Abstract

Major depressive disorder (MDD) is a psychiatric disorder, characterized by periods of low mood of more than two weeks, loss of interest in normally enjoyable activities and behavioral changes. MDD is a complex disorder and does not have a single genetic cause. In 2009 a genome wide association study (GWAS) was performed on the Dutch GAIN-MDD cohort. Many of the top signals of this GWAS mapped to a region spanning the gene PCLO, and the non-synonymous coding single nucleotide polymorphism (SNP) rs2522833 in the PCLO gene became genome wide significant after post-hoc analysis. We performed resequencing of PCLO, GRM7, and SLC6A4 in 50 control samples from the GAIN-MDD cohort, to detect new genomic variants. Subsequently, we genotyped these variants in the entire GAIN-MDD cohort and performed association analysis to investigate if rs2522833 is the causal variant or simply in linkage disequilibrium with a more associated variant. GRM7 and SLC6A4 are both candidate genes for MDD from literature. We aimed to gather more evidence that rs2522833 is indeed the causal variant in the GAIN-MDD cohort or to find a previously undetected common variant in either PCLO, GRM7, or SLC6A4 with a higher association in this cohort. After next generation sequencing and association analysis we excluded the possibility of an undetected common variant to be more associated. For neither PCLO nor GRM7 we found a more associated variant. For SLC6A4, we found a new SNP that showed a lower P-value (P = 0.07) than in the GAIN-MDD GWAS (P = 0.09). However, no evidence for genome-wide significance was found. Although we did not take into account rare variants, we conclude that our results provide further support for the hypothesis that the non-synonymous coding SNP rs2522833 in the PCLO gene is indeed likely to be the causal variant in the GAIN-MDD cohort.

Indexed as

Cohort StudiesCytoskeletal ProteinsEpistasis, GeneticGenome-Wide Association StudyHaplotypesHumansMajor Depressive DisorderNetherlandsNeuropeptidesPolymorphism, Single NucleotidePromoter Regions, GeneticReceptors, Metabotropic GlutamateSerotonin Plasma Membrane Transport ProteinsCytoskeletal Proteinsmetabotropic glutamate receptor 7NeuropeptidesPCLO protein, humanReceptors, Metabotropic GlutamateSerotonin Plasma Membrane Transport ProteinsSLC6A4 protein, human

Identifiers

PMID24278217
PMCPMC3836783
OpenAlexW2114699713

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.